26Apr 2015

Advanced Glycation End Products (AGEs) level and insulin resistance in women with gestational diabetes

  • Abstract
  • Cite This Article as
  • Corresponding Author

Objective: to study the level of the oxidative stress marker, Advanced Glycation End products (AGE)s in women with gestational diabetes, and to assess its usage as a biomarker in addition to the insulin resistance indexes in the diagnosis of gestational diabetes. Methods: A case control study was carried out from January to June/2014. Sixty pregnant women at third trimester between (37-41) weeks of gestation and average age between (18-45) years old were enrolled in this study. They were admitted to different hospitals in Baghdad. All cases selected for this study underwent elective caesarian section. Thirty healthy pregnant women at the same average of age involved as control group. Patients and controls were comparable in age. Results: Patient\'s AGEs, FSG, HbA1c, C-peptide concentration and HOMA-IR were found significantly increased when compared vs. the control (p-value <0.0001). While patient\'s insulin level showed no significant difference (p-value 0.062) when compared with control. Conclusion: Depending on the ROC analysis, AGEs was found more accurate than HOMA-IR. So, it may be consider as a good biomarker in addition to the HOMA-IR in diagnosis women with gestational diabetes.


[Zainab NE. Aziz, Rayah S. Baban and May F. M. Al-Habib (2015); Advanced Glycation End Products (AGEs) level and insulin resistance in women with gestational diabetes Int. J. of Adv. Res. 3 (4). 0] (ISSN 2320-5407). www.journalijar.com


Zainab NE. Aziz B.Sc., Rayah S. Baban PhD and May F. M. Al-Habib PhD


Share this article